Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

Next Previous
Trial Profile

A Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix in Adult Subjects With Irritable Bowel Syndrome (IBS) Subtypes IBS-C and IBS-D

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CJRB 205 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors 4D Pharma PLC

    • Most Recent Events

    • 09 May 2023 Results (n=260) evaluating the microbiota, presented at the Digestive Disease Week 2023.
    • 11 Nov 2022 Results reporting safety and efficacy of MRx1234 in patients with irritable bowel syndrome published in the Alimentary Pharmacology and Therapeutics
    • 31 Mar 2022 According to a 4D Pharma media release, the company plans to provide update and guidance on Phase II study of Blautix in patients with irritable bowel syndrome (IBS) in 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top